N-(6-Cyano-1,2,3,4-tetrahydro-3-quinolinyl)benzene-sulfonamide | 219862-37-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-(6-Cyano-1,2,3,4-tetrahydro-3-quinolinyl)benzene-sulfonamide
• 英文别名: N-(6-Cyano-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide；N-(6-cyano-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide
• CAS: 219862-37-0
• 化学式: C₁₆H₁₅N₃O₂S
• 分子量: 313.38
• InChiKey: MHYDATSAXQNFJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  90.4
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(6-Cyano-1,2,3,4-tetrahydro-3-quinolinyl)benzene-sulfonamide 在 三乙基硅烷 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 N-[6-Cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-N-methyl-benzenesulfonamide
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors

  摘要：

  Tetrahydroquinoline-based small molecule inhibitors of farnesyltransferase (FT) have been identified. Lead compounds were shown to have nanomolar to sub-nanomolar activity in biochemical assays with excellent potency in a Ras-mutated cellular reversion assay. BMS-316810 (9e), a 0.7 nM FT inhibitor, was orally-active in a nude mouse tumor allograft efficacy study. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.02.004
• 作为产物：
  描述：

  (6-Bromo-1,2,3,4-tetrahydro-3-quinolinyl)carbamic acid, 1,1-dimethylethyl ester 在 四(三苯基膦)钯 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 N-(6-Cyano-1,2,3,4-tetrahydro-3-quinolinyl)benzene-sulfonamide
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors

  摘要：

  Tetrahydroquinoline-based small molecule inhibitors of farnesyltransferase (FT) have been identified. Lead compounds were shown to have nanomolar to sub-nanomolar activity in biochemical assays with excellent potency in a Ras-mutated cellular reversion assay. BMS-316810 (9e), a 0.7 nM FT inhibitor, was orally-active in a nude mouse tumor allograft efficacy study. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.02.004

文献信息

• Inhibitors of farnesyl protein transferase
  申请人：Bristol-Myers Squibb Company

  公开号：US06387926B1

  公开（公告）日：2002-05-14

  Disclosed are quinoline and benzazepine derivatives that inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogenic protein Ras. Thus, the compounds are useful as anti-cancer agents. The compounds are also useful in the treatment of diseases other than cancer.

  本文披露了抑制法尼基蛋白转移酶（FTase）和致癌蛋白Ras法尼基化的喹啉和苯并氮杂环衍生物。因此，这些化合物可用作抗癌药物。这些化合物还可用于治疗癌症以外的疾病。
• Tetrahydroquinoline derivatives as cannabinoid receptor modulators
  申请人：Sun Chongqing

  公开号：US20050014786A1

  公开（公告）日：2005-01-20

  The invention provides for compounds of formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of eating disorders, metabolic disorders, obesity, cognitive disorders, neurological disorders, pain disorders, inflammation disorders, in the promotion of smoking cessation and for the treatment of other psychiatric disorders Also provided are pharmaceutical compositions containing such compounds and pharmaceutical combinations of the compounds of the invention with other therapeutic agents.

  该发明提供了式I的化合物，其中取代基如本文所述。进一步提供了使用这些化合物治疗进食障碍、代谢障碍、肥胖症、认知障碍、神经系统障碍、疼痛障碍、炎症障碍、促进戒烟和治疗其他精神障碍的方法。还提供了含有这些化合物的制药组合物和该发明化合物与其他治疗剂的制药组合。
• TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS
  申请人：Sun Chongqing

  公开号：US20080194625A1

  公开（公告）日：2008-08-14

  The invention provides for compounds of formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of eating disorders, metabolic disorders, obesity, cognitive disorders, neurological disorders, pain disorders, inflammation disorders, in the promotion of smoking cessation and for the treatment of other psychiatric disorders Also provided are pharmaceutical compositions containing such compounds and pharmaceutical combinations of the compounds of the invention with other therapeutic agents.

  本发明提供了式I的化合物，其中取代基如本文所述。还提供了使用这些化合物治疗进食障碍、代谢障碍、肥胖症、认知障碍、神经系统疾病、疼痛障碍、炎症障碍、促进戒烟和治疗其他精神障碍的方法。还提供了含有这些化合物的药物组合物以及本发明化合物与其他治疗剂的药物组合物。
• EP0994856A4
  申请人：——

  公开号：EP0994856A4

  公开（公告）日：2000-12-06
• INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：EP0994856A1

  公开（公告）日：2000-04-26